0.585
0.03 (5.41%)
| Penutupan Terdahulu | 0.555 |
| Buka | 0.570 |
| Jumlah Dagangan | 102,188 |
| Purata Dagangan (3B) | 308,384 |
| Modal Pasaran | 80,064,312 |
| Harga / Buku (P/B) | 8.61 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,517.31% |
| EPS Cair (TTM) | -0.030 |
| Nisbah Semasa (MRQ) | 16.69 |
| Aliran Tunai Operasi (OCF TTM) | -2.79 M |
| Pulangan Atas Aset (ROA TTM) | -21.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (AU) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | CLEO DIAGN FPO [COV] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.50 |
|
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company’s first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| % Dimiliki oleh Orang Dalam | 76.28% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |